Recertify to Continue Dispensing Clozapine

November 2015

Please see the FDA notice concerning Clozapine REMS program updates/deadline extensions.

A SINGLE new registry will streamline clozapine use and dispensing.

Clozapine is very effective for schizophrenia. But it's often considered a last resort due to neutropenia and other side effects.

The new Clozapine REMS Program is now the ONLY registry available.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Diabetes Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon
Vaccines Wait ≥ 1 Year Between Pneumococcal Vaccines in Seniors
Diabetes Consider NPH and Regular Insulin INSTEAD of Insulin Analogs
Aspirin Recommend Aspirin to FEWER Patients to Prevent First Heart Attack or Stroke
Psychiatry Recertify to Continue Dispensing Clozapine
Sinusitis Explain Chronic Sinusitis is Usually Due to Inflammation...Not Infection
Supplements Tell Patients to Forget About Using Prevagen for Memory
Sports Medicine Recommend Baby Oil to Remove Kinesiology Tape
Practice Incorporate PDMP Review Into Your Pharmacy Workflow
Chronic Pain Suggest Alternatives for Neuropathic Pain Prior to Using Opioids
Pediatrics Explain Why Just One Dose of Tramadol Can be Risky in Children